Drug Trial Radar · NCT06793995
Effect of Food and Age on the Pharmacokinetics of LY03017
Last checked: Nov 20, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
26
Planned (sponsor's estimate)
Start
Feb 2025
Primary completion
Oct 31, 2025
Study completion Oct 31, 2025
Sponsor
- Lead sponsor
- Luye Pharma Group Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study consists of 2 parts. Part A is a randomized, open-label, 2-period, crossover study to evaluate the food effect of LY03017 in healthy adults. Part B is a single-arm study to evaluate the safety and pharmacokinetics of LY03017 in elderly volunteers.
Conditions
- Alzheimer's Disease Psychosis
- Parkinson Disease Psychosis
- Negative Symptoms of Schizophrenia
Interventions
LY03017Drug
single dose,administered orally for each period
LY03017Drug
single dose,administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed concentration (Cmax) of LPM526000133 in plasmaTime frame: Up to 96 hours after the last dose
- The area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞) of LPM526000133 in plasmaTime frame: Up to 96 hours after the last dose
- Area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUC[0-last]) of LPM526000133 in plasmaTime frame: Up to 96 hours after the last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Mental Health Center
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.